Scientific article
English

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients

Published in

Clinical infectious diseases, vol. 20, no. 3, p. 531-541

Publication date

1995

Abstract

To evaluate combined prophylaxis for Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis, 533 patients with symptomatic human immunodeficiency virus infection and/or CD4 lymphocyte counts of < 200/microL were randomized to receive dapsone/pyrimethamine (200/75 mg once weekly) or aerosolized pentamidine (300 mg every 4 weeks). The median CD4 lymphocyte count was 110/microL; 47.5% were seropositive for toxoplasma antibodies. The median duration of follow-up was 483 days. In the intent-to-treat analysis, 12 cases of PCP and 14 of toxoplasmic encephalitis occurred in the dapsone/pyrimethamine group and 13 and 20 cases, respectively, in the aerosolized pentamidine group (adjusted relative risk for toxoplasmosis, 0.56; P =.10). However, only two of the 14 cases of toxoplasmic encephalitis in the dapsone/pyrimethamine group developed during actual treatment. The mortality among the two groups was similar. Dapsone/pyrimethamine was not tolerated by 30% of participants. A subanalysis of 240 matched, tolerant patients yielded a relative risk for toxoplasmosis of 0.21 (P =.014), a result favoring the use of dapsone/pyrimethamine. Dapsone/pyrimethamine was as effective as aerosolized pentamidine as prophylaxis for PCP and significantly reduced the incidence of toxoplasmic encephalitis among those participants who tolerated it.

Keywords

  • AIDS-Related Opportunistic Infections/epidemiology/ prevention & control
  • Administration, Inhalation
  • Adult
  • Animals
  • Dapsone/administration & dosage/adverse effects/ therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Encephalitis/complications/epidemiology/parasitology/ prevention & control
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Pentamidine/administration & dosage/adverse effects/ therapeutic use
  • Pneumonia, Pneumocystis/complications/epidemiology/ prevention & control
  • Pyrimethamine/administration & dosage/adverse effects/ therapeutic use
  • Toxoplasmosis, Cerebral/complications/epidemiology/ prevention & control

Citation (ISO format)

OPRAVIL, Milos et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. In: Clinical infectious diseases, 1995, vol. 20, n° 3, p. 531–541. doi: 10.1093/clinids/20.3.531

Main files (1)

Article

Identifiers

Journal ISSN

1058-4838
696views
0downloads

Technical informations

Creation

21/06/2010 10:25:33

First validation

21/06/2010 10:25:33

Update

14/03/2023 15:44:51

Status update

14/03/2023 15:44:51

Last indexation

29/10/2024 15:15:51
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated